| Study | Reason for exclusion |
|---|---|
| Athyros 2002 | Publication type letter, no control group, not enough information reported. |
| Braaskamp 2015b | Cohort study. |
| Braaskamp 2015c | Clinical trial without randomization. |
| Carreau 2011 | Cohort study. |
| Chan 2016 | No control group without medication. |
| Dirisamer 2003 | Clinical trial, no control group. |
| Gandelman 2011 | Clinical trial, no control group, open‐label. |
| Hedman 2003 | Clinical trial, no control group. |
| Hedman 2005 | Clinical trial, no control group. |
| Lambert 1996 | Clinical trial, no control group. |
| Langslet 2016 | Clinical trial, no placebo control group |
| McCrindle 2002 | Randomised cross‐over trial, comparison unacceptable (i.e. combination of 2 active drugs): one intervention was 10 mg pravastatin plus 5 g colestipol and the other 10 g colestipol. |
| Raal 1997 | Clinical trial, no control group. |
| Sinzinger 2004 | Cohort study. |
| Stefanutti 1999 | Clinical trial, control diet alone, controls were not clearly defined, e.g. the diagnostic criteria for heterozygous FH not reported, only age of the participants given. |
| Stein 1989 | Cohort study. |
| Stein 2016 | Participants had homozygous FH. |
| Tada 2016 | No control group without medication. |
| Teramoto 2016 | PCSK 9 inhibitor used as add‐on therapy and also not only people with FH included. |
| van der Graaf 2006 | Clinical trial, no control group. |
FH: familial hypercholesterolemia